Eli Lilly and Company (NYSE:LLY) – Eli Lilly: Cymbalta Patent Expiry Quantified

[at Seeking Alpha] – On December 11th, Eli Lilly ( LLY ) will lose U.S. patent protection of its antidepressant blockbuster Cymbalta (duloxetine) and the product’s U.S. sales are expected to decline significantly. . . . → Read More: Eli Lilly and Company (NYSE:LLY) – Eli Lilly: Cymbalta Patent Expiry Quantified Similar posts: Altria Group Inc. (NYSE:MO) – Altria Beats on Q3 Earnings, Revs [Zacks] – Cigarette maker Altria Group Inc.’s adjusted earnings... Can Eli Lilly Earnings Keep Up With Merck and Pfizer? – Merck & Co. Inc. (NYSE:MRK) [at Motley Fool] – Like many of its peers,... Stock Update: Pfizer Inc. (NYSE:PFE) – Can Eli Lilly Earnings Keep Up With Merck and Pfizer? [at Motley Fool] – Like many of its peers,...